| scholarly article | Q13442814 |
| P50 | author | Paul Heath | Q61163339 |
| Katrin Susanne Kohl | Q65555419 | ||
| Scott A Halperin | Q65555423 | ||
| P2093 | author name string | Jane Gidudu | |
| Anne Schuind | |||
| Bernard Hoet | |||
| Frederick Varricchio | |||
| Edward Rothstein | |||
| Renald Hennig | |||
| Wikke Walop | |||
| Sandra Jo Hammer | |||
| Brighton Collaboration Local Reactions Working Group for a Local Reaction at or near Injection Site | |||
| P2860 | cites work | Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses | Q27860840 |
| Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting | Q27861077 | ||
| The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials | Q29619671 | ||
| Nodule at injection site as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation | Q30890134 | ||
| Rash including mucosal involvement: case definition and guidelines for collection, analysis, and presentation of immunization safety data | Q31107914 | ||
| Abscess at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data | Q31114324 | ||
| Swelling at or near injection site: case definition and guidelines for collection, analysis and presentation of immunization safety data | Q31114573 | ||
| Cellulitis at injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data | Q31114574 | ||
| Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data | Q31114967 | ||
| Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring | Q34182372 | ||
| BCG vaccination scar associated with better childhood survival in Guinea-Bissau | Q34385915 | ||
| Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings | Q35237369 | ||
| Combined vaccination against yellow fever and typhoid fever: a comparative trial | Q38872328 | ||
| Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana | Q39429149 | ||
| Associated or combined vaccination of Brazilian infants with a conjugate Haemophilus influenzae type b (Hib) vaccine, a diphtheria-tetanus-whole-cell pertussis vaccine and IPV or OPV elicits protective levels of antibodies against Hib. | Q40616982 | ||
| Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children | Q40628298 | ||
| Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates | Q40700943 | ||
| Reactogenicity and safety of meningococcal A and C vaccine in Saudi children | Q40708233 | ||
| Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children | Q40726130 | ||
| Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies | Q40961043 | ||
| Lichenoid reaction to hepatitis B vaccination | Q41592130 | ||
| Papulonodular lichenoid and pseudolymphomatous reaction at the injection site of hepatitis B virus vaccination | Q45731030 | ||
| Arthus reaction to recombinant hepatitis B virus vaccine | Q45736026 | ||
| Dose–Response to a Two-Component Acellular Pertussis Vaccine In Infants and Comparison with Whole-cell Vaccine | Q57954228 | ||
| Immunogenicity and safety of a liquid combination of DTP-PRP-T [corrected] vs lyophilized PRP-T reconstituted with DTP | Q73145891 | ||
| A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers | Q73594815 | ||
| Bacillus Calmette-Guérin sepsis: shift of an intended local toward a detrimental systemic cytotoxic immune response | Q74249904 | ||
| Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule | Q77333462 | ||
| Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at | Q77489381 | ||
| Lichen scrofulosorum-like eruption localized to multipuncture BCG vaccination site | Q78062111 | ||
| The development of standardized case definitions and guidelines for adverse events following immunization | Q80074697 | ||
| Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents | Q83058106 | ||
| P433 | issue | 52 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunization | Q1415366 |
| immunization safety | Q105259234 | ||
| P304 | page(s) | 6800-6813 | |
| P577 | publication date | 2008-10-23 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | A local reaction at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data | |
| P478 | volume | 26 |
| Q30412637 | A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-possible stimulated reporting? |
| Q91609176 | A grading system for local skin reactions developed for clinical trials of an intradermal and transcutaneous ETEC vaccine |
| Q33987686 | A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children |
| Q91068795 | ADVANCE system testing: Can safety studies be conducted using electronic healthcare data? An example using pertussis vaccination |
| Q37384720 | Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more |
| Q45897169 | An investigation of three injections techniques in reducing local injection pain with a human papillomavirus vaccine: a randomized trial |
| Q44501609 | Comparison of the tolerability of an acellular pertussis-containing vaccine given as the fifth booster dose in differently primed children |
| Q33763060 | Diarrhea: case definition and guidelines for collection, analysis, and presentation of immunization safety data |
| Q31103326 | Facial nerve palsy including Bell's palsy: Case definitions and guidelines for collection, analysis, and presentation of immunisation safety data |
| Q41085695 | First clinical results of a personalized immunotherapeutic vaccine against recurrent, incompletely resected, treatment-resistant glioblastoma multiforme (GBM) tumors, based on combined allo- and auto-immune tumor reactivity |
| Q26250281 | Guideline for collection, analysis and presentation of safety data in clinical trials of vaccines in pregnant women |
| Q22251433 | Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data |
| Q34240937 | Immunization site pain: case definition and guidelines for collection, analysis, and presentation of immunization safety data |
| Q40164989 | Implementation of pertussis immunization in health-care personnel |
| Q38779212 | Injection Site Lichenoid Dermatitis Following Pneumococcal Vaccination: Report and Review of Cutaneous Conditions Occurring at Vaccination Sites |
| Q24187107 | Needle size for vaccination procedures in children and adolescents |
| Q24200692 | Needle size for vaccination procedures in children and adolescents |
| Q57688932 | Needle size for vaccination procedures in children and adolescents |
| Q57182362 | Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women |
| Q91556278 | Reports of atypical shoulder pain and dysfunction following inactivated influenza vaccine, Vaccine Adverse Event Reporting System (VAERS), 2010-2017 |
| Q36818929 | Safety of Tdap vaccine in pregnant women: an observational study |
| Q38846084 | Safety of a Trivalent Inactivated Influenza Vaccine in Health Care Workers in Kurdistan Province, Western Iran; A Longitudinal Follow-up Study |
| Q36278634 | Safety of measles-containing vaccines in post-marketing surveillance in Anhui, China |
| Q37992392 | Safety reporting in developing country vaccine clinical trials-a systematic review |
| Q83798645 | Surveillance of vaccine safety: comparison of parental reports with routine surveillance and a clinical trial |
| Q36100736 | Template protocol for clinical trials investigating vaccines--focus on safety elements |
| Q34227424 | Vaccination in elite athletes |
| Q33168249 | Vaccine adverse events in a safety net healthcare system and a managed care organization. |
Search more.